Literature DB >> 23139242

iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration.

Ruchira Singh1, Wei Shen, David Kuai, Jessica M Martin, Xiangrong Guo, Molly A Smith, Enio T Perez, M Joseph Phillips, Joseph M Simonett, Kyle A Wallace, Amelia D Verhoeven, Elizabeth E Capowski, Xiaoqing Zhang, Yingnan Yin, Patrick J Halbach, Gerald A Fishman, Lynda S Wright, Bikash R Pattnaik, David M Gamm.   

Abstract

Best disease (BD) is an inherited degenerative disease of the human macula that results in progressive and irreversible central vision loss. It is caused by mutations in the retinal pigment epithelium (RPE) gene BESTROPHIN1 (BEST1), which, through mechanism(s) that remain unclear, lead to the accumulation of subretinal fluid and autofluorescent waste products from shed photoreceptor outer segments (POSs). We employed human iPS cell (hiPSC) technology to generate RPE from BD patients and unaffected siblings in order to examine the cellular and molecular processes underlying this disease. Consistent with the clinical phenotype of BD, RPE from mutant hiPSCs displayed disrupted fluid flux and increased accrual of autofluorescent material after long-term POS feeding when compared with hiPSC-RPE from unaffected siblings. On a molecular level, RHODOPSIN degradation after POS feeding was delayed in BD hiPSC-RPE relative to unaffected sibling hiPSC-RPE, directly implicating impaired POS handling in the pathophysiology of the disease. In addition, stimulated calcium responses differed between BD and normal sibling hiPSC-RPE, as did oxidative stress levels after chronic POS feeding. Subcellular localization, fractionation and co-immunoprecipitation experiments in hiPSC-RPE and human prenatal RPE further linked BEST1 to the regulation and release of endoplasmic reticulum calcium stores. Since calcium signaling and oxidative stress are critical regulators of fluid flow and protein degradation, these findings likely contribute to the clinical picture of BD. In a larger context, this report demonstrates the potential to use patient-specific hiPSCs to model and study maculopathies, an important class of blinding disorders in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139242      PMCID: PMC3542866          DOI: 10.1093/hmg/dds469

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  60 in total

1.  Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.

Authors:  A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Isolation and provisional identification of plasma membrane populations from cultured human retinal pigment epithelium.

Authors:  A K Mircheff; S S Miller; D B Farber; M E Bradley; W T O'Day; D Bok
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-05       Impact factor: 4.799

Review 3.  Best's vitelliform dystrophy.

Authors:  C F Blodi; E M Stone
Journal:  Ophthalmic Paediatr Genet       Date:  1990-03

4.  The vitelliform macular dystrophy protein defines a new family of chloride channels.

Authors:  Hui Sun; Takashi Tsunenari; King-Wai Yau; Jeremy Nathans
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

5.  Clinical expression of Best's vitelliform macular dystrophy in Swedish families with mutations in the bestrophin gene.

Authors:  V Ponjavic; L Eksandh; S Andréasson; K Sjöström; B Bakall; S Ingvast; C Wadelius; B Ehinger
Journal:  Ophthalmic Genet       Date:  1999-12       Impact factor: 1.803

6.  Hereditary maculardegeneration (HMD) in 246 cases traced to one gene-source in central Sweden.

Authors:  S Nordström; Y Barkman
Journal:  Hereditas       Date:  1977-02-03       Impact factor: 3.271

7.  A histopathologic study of Best's macular dystrophy.

Authors:  G T Frangieh; W R Green; S L Fine
Journal:  Arch Ophthalmol       Date:  1982-07

8.  Long-term evaluation of patients with Best's vitelliform dystrophy.

Authors:  C W Mohler; S L Fine
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

9.  Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement.

Authors:  W Daniel Stamer; Dean Bok; Jane Hu; Glenn J Jaffe; Brian S McKay
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-06       Impact factor: 4.799

10.  Phenotypic variation including retinitis pigmentosa, pattern dystrophy, and fundus flavimaculatus in a single family with a deletion of codon 153 or 154 of the peripherin/RDS gene.

Authors:  R G Weleber; R E Carr; W H Murphey; V C Sheffield; E M Stone
Journal:  Arch Ophthalmol       Date:  1993-11
View more
  109 in total

1.  Quantitative Fundus Autofluorescence in Best Vitelliform Macular Dystrophy: RPE Lipofuscin is not Increased in Non-Lesion Areas of Retina.

Authors:  Janet R Sparrow; Tobias Duncker; Russell Woods; François C Delori
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 2.  Plasma membrane protein polarity and trafficking in RPE cells: past, present and future.

Authors:  Guillermo L Lehmann; Ignacio Benedicto; Nancy J Philp; Enrique Rodriguez-Boulan
Journal:  Exp Eye Res       Date:  2014-09       Impact factor: 3.467

3.  Generation of highly enriched populations of optic vesicle-like retinal cells from human pluripotent stem cells.

Authors:  Sarah K Ohlemacher; Clara L Iglesias; Akshayalakshmi Sridhar; David M Gamm; Jason S Meyer
Journal:  Curr Protoc Stem Cell Biol       Date:  2015-02-02

Review 4.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

5.  Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.

Authors:  Luke A Wiley; Erin R Burnight; Arlene V Drack; Bailey B Banach; Dalyz Ochoa; Cathryn M Cranston; Robert A Madumba; Jade S East; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Hum Gene Ther       Date:  2016-07-11       Impact factor: 5.695

Review 6.  Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells.

Authors:  Priya Srikanth; Tracy L Young-Pearse
Journal:  J Neurogenet       Date:  2014-03-17       Impact factor: 1.250

7.  Quantitative fundus autofluorescence and optical coherence tomography in best vitelliform macular dystrophy.

Authors:  Tobias Duncker; Jonathan P Greenberg; Rithambara Ramachandran; Donald C Hood; R Theodore Smith; Tatsuo Hirose; Russell L Woods; Stephen H Tsang; François C Delori; Janet R Sparrow
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-13       Impact factor: 4.799

Review 8.  Lessons learned from quantitative fundus autofluorescence.

Authors:  Janet R Sparrow; Tobias Duncker; Kaspar Schuerch; Maarjaliis Paavo; Jose Ronaldo Lima de Carvalho
Journal:  Prog Retin Eye Res       Date:  2019-08-28       Impact factor: 21.198

Review 9.  BEST1: the Best Target for Gene and Cell Therapies.

Authors:  Tingting Yang; Sally Justus; Yao Li; Stephen H Tsang
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

10.  BESTROPHIN1 mutations cause defective chloride conductance in patient stem cell-derived RPE.

Authors:  Yasmin Moshfegh; Gabriel Velez; Yao Li; Alexander G Bassuk; Vinit B Mahajan; Stephen H Tsang
Journal:  Hum Mol Genet       Date:  2016-05-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.